scPharmaceuticals gets FDA approval of its sNDA expanding FUROSCIX indication

MF3d/E+ via Getty Images scPharmaceuticals ( NASDAQ: SCPH ) said on Thursday that the FDA approved its supplemental New Drug Application to expand FUROSCIX indication in kidney disease treatment. The sNDA expanded FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome. FUROSCIX is expected to be available for chronic kidney disease patients in April 2025.

More on scPharmaceuticals Seeking Alpha’s Quant Rating on scPharmaceuticals Historical earnings data for scPharmaceuticals Financial information for scPharmaceuticals.